The difference between acotinib and osimertinib

Acalabrutinib and Osimertinib (Osimertinib) are two targeted therapies. Although they are similar in name, their mechanisms of action, indications and clinical application areas are different. The differences between these two drugs are detailed below:

1.Mechanism of action:

Acotinib: Acotinib is a BTK inhibitor that mainly acts on BTK in the B cell receptor signaling pathway. It inhibits the growth and proliferation of leukemia and lymphoma cells by selectively inhibiting the activity of BTK and blocking the signaling pathways of abnormal B cells.

Osimertinib: Osimertinib is an EGFR (Epidermal Growth Factor Receptor) mutation-specific inhibitor, mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). It inhibits the growth and spread of tumor cells by selectively inhibiting the activity of EGFR and interfering with the EGFR signaling pathway.

2.Indications:

Acotinib: Acotinib is mainly used to treat specific types of leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), small cell lymphoma (SLL), follicular lymphoma Lymphoma (FL) and diffuse largeB cell lymphoma (DLBCL), etc.

Osimertinib: Osimertinib is mainly used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC), especially those who have experienced first-line treatment failure or drug resistance.

3.Drug resistance:

Acotinib: Although acotinib has shown promising efficacy in treating certain types of leukemias and lymphomas, resistance may develop in some patients. In this case, doctors may need to consider switching treatment options or adopting other treatment strategies.

Osimertinib: Compared with traditional EGFR inhibitors, osimertinib has better efficacy in patients with EGFR T790M drug-resistant NSCLC and is therefore considered an effective treatment option.

4.Adverse reactions:

Acotinib: Common adverse reactions of acotinib include thrombocytopenia, neutropenia, headache, myalgia, fatigue, etc.

Osimertinib: Common adverse reactions of osimertinib include rash, diarrhea, fatigue, cough, pneumonia, etc. A small number of patients may develop severe pulmonary toxicities, such as interstitial lung disease.

5.Clinical application areas:

Acotinib: Acotinib is mainly used for the treatment of hematological tumors, such as CLL, SLL, FL and DLBCL, etc.

Osimertinib: Osimertinib is mainly used to treat EGFR mutation-positive NSCLC and is an important choice for first-line and later-line treatment.

In summary, although acotinib and osimertinib are both targeted therapeutic drugs, their mechanisms of action, indications, drug resistance, adverse reactions and clinical application fields are different. Doctors should choose the most appropriate treatment options and drugs based on the patient's specific situation and type of disease.